[go: up one dir, main page]

TR200103333T2 - Dayanıklığı ve biyolojik uygunluğu iyileştiren yardımcı ilaç (SBA) - Google Patents

Dayanıklığı ve biyolojik uygunluğu iyileştiren yardımcı ilaç (SBA)

Info

Publication number
TR200103333T2
TR200103333T2 TR2001/03333T TR200103333T TR200103333T2 TR 200103333 T2 TR200103333 T2 TR 200103333T2 TR 2001/03333 T TR2001/03333 T TR 2001/03333T TR 200103333 T TR200103333 T TR 200103333T TR 200103333 T2 TR200103333 T2 TR 200103333T2
Authority
TR
Turkey
Prior art keywords
sba
adjuvant
biological compatibility
immune response
auxiliary drug
Prior art date
Application number
TR2001/03333T
Other languages
English (en)
Inventor
Helmut Müller Rainer
Grubhofer Nikolaus
Olbrich Carsten
Original Assignee
Pharmasol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasol Gmbh filed Critical Pharmasol Gmbh
Publication of TR200103333T2 publication Critical patent/TR200103333T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bulus, bir veya birçok antijenle birlikte enjekte edildiginde vücut sivilarindan ileri gelen ve selüler bagisiklik tepkisini arttiran dayanikligi ve biyolojik uygunlugu iyilestirilmis bir yardimci ilaç (SBA) içermektedir. Yardimci ilaç kati lipitler ya da kati lipit karisimlari bazinda partiküllerden olusmaktadir. Kullanim olanaklari, daha etkili ve hazmi daha kolay asi maddeleri üretmek, insanlarin ve hayvanlarin asilanmasi, ayni zamanda antikorlarin kazanilmasidir. Partikül büyüklügünun, yükünün ve üst yüzey özelliklerinin seçimiyle bagisiklik tepkisinin gücü hedefli modüle edilebilir ve ilaveten türe uygunlastirilabilir. SBA'ya baska yardimci ilaçlar da örnegin GMDP gibi moleküler yardimci ilaçlar eklenebilir, böylece selüler bagisiklik tepkisi ilaveten arttirilir.
TR2001/03333T 1999-05-20 2000-05-19 Dayanıklığı ve biyolojik uygunluğu iyileştiren yardımcı ilaç (SBA) TR200103333T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19923256 1999-05-20

Publications (1)

Publication Number Publication Date
TR200103333T2 true TR200103333T2 (tr) 2002-04-22

Family

ID=7908697

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03333T TR200103333T2 (tr) 1999-05-20 2000-05-19 Dayanıklığı ve biyolojik uygunluğu iyileştiren yardımcı ilaç (SBA)

Country Status (11)

Country Link
EP (1) EP1183045A2 (tr)
JP (1) JP2003500365A (tr)
KR (1) KR20020012221A (tr)
AU (2) AU5214200A (tr)
BR (1) BR0010823A (tr)
CA (1) CA2373239A1 (tr)
DE (1) DE10024788A1 (tr)
MX (1) MXPA01011660A (tr)
TR (1) TR200103333T2 (tr)
WO (2) WO2000071154A2 (tr)
ZA (1) ZA200109147B (tr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2373239A1 (en) * 1999-05-20 2000-11-30 Pharmasol Gmbh Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
ES2379267T3 (es) * 2003-10-23 2012-04-24 Novartis Vaccines And Diagnostics, Inc. Composiciones estabilizadas
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
KR101273120B1 (ko) 2004-08-20 2013-06-13 맨카인드 코포레이션 다이케토피페라진 합성의 촉매 작용
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
KR101486829B1 (ko) * 2005-09-14 2015-01-29 맨카인드 코포레이션 결정질 미립자 표면에 대한 활성제의 친화력의 증가를 기반으로 하는 약물 제제의 방법
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
TWI677355B (zh) 2008-06-13 2019-11-21 美商曼凱公司 用於藥物傳輸之乾粉吸入器及系統
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
MY186975A (en) 2009-06-12 2021-08-26 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
US8925726B2 (en) 2011-04-01 2015-01-06 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
AU2013256565B2 (en) 2012-04-30 2015-12-03 Ossur Hf Prosthetic device, system and method for increasing vacuum attachment
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
BE1024228B1 (fr) * 2015-12-08 2017-12-21 Glaxosmithkline Biologicals Sa Nouvelles formulations d'adjuvants
KR102721917B1 (ko) * 2022-05-31 2024-11-04 우리이앤엘 주식회사 비타민 함유 리포좀의 제조 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
AU5068999A (en) * 1998-07-31 2000-02-21 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
CA2373239A1 (en) * 1999-05-20 2000-11-30 Pharmasol Gmbh Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response

Also Published As

Publication number Publication date
JP2003500365A (ja) 2003-01-07
WO2000071154A3 (de) 2001-06-28
BR0010823A (pt) 2002-03-05
WO2000071154A2 (de) 2000-11-30
AU5809100A (en) 2000-12-12
DE10024788A1 (de) 2000-11-23
KR20020012221A (ko) 2002-02-15
AU5214200A (en) 2000-12-12
ZA200109147B (en) 2002-05-08
MXPA01011660A (es) 2004-04-05
WO2000071077A2 (de) 2000-11-30
EP1183045A2 (de) 2002-03-06
CA2373239A1 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
TR200103333T2 (tr) Dayanıklığı ve biyolojik uygunluğu iyileştiren yardımcı ilaç (SBA)
WO2005007673A3 (en) Immunogenic peptides
ATE463505T1 (de) Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
BRPI0516463A (pt) cánula escalonada e conjunto de cánula
WO1999040936A3 (en) Pneumococcal and meningococcal vaccines formulated with interleukin-12
Brodie et al. Immunomodulatory effects of the Lutzomyia longipalpis salivary gland protein maxadilan on mouse macrophages
Li et al. Efficacy of Eimeria tenella rhomboid-like protein as a subunit vaccine in protective immunity against homologous challenge
EP2484375A3 (en) Vaccine composition containing synthetic adjuvant
PL365951A1 (pl) Związki oraz sposoby leczenia i diagnozowania infekcji Chlamydia
ATE443768T1 (de) Impfstoff gegen staphylokokken-vergiftung
ATE442866T1 (de) Fusionsproteine aus mycobakterium tuberculosis
DK1910408T3 (da) Bifunktionelle proteinankre
Beltrán-Beck et al. Tonsils of the soft palate do not mediate the response of pigs to oral vaccination with heat-inactivated Mycobacterium bovis
WO2009070507A3 (en) Anaplasma phagocytophilum (aph) antigens and antibodies specific for anaplasma
Whelan et al. Modulation of the bovine delayed-type hypersensitivity responses to defined mycobacterial antigens by a synthetic bacterial lipopeptide
WO2005099361A3 (en) MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
MA32376B1 (fr) VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME
BRPI0208124B8 (pt) uso de um anticorpo igy imunologicamente específico para a proteína paa associada à virulência de escherichia coli de ligação e eliminação (aeec)
TW200619228A (en) Immunogenic compositions of staphylococcus epidermidis polypeptide antigens
Bortolatto et al. Adsorption of Toll‐like receptor 4 agonist to alum‐based tetanus toxoid vaccine dampens pro‐T helper 2 activities and enhances antibody responses
PL1649287T3 (pl) Ocena szczepionek zawierających adjuwanty
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
WO2006117538A3 (en) Assays for diagnosis of tuberculosis and uses thereof
Shlyakhov et al. Evaluation of Bacillus anthracis extractable antigen for testing anthrax immunity
Borody et al. Lactoferrin: milking ulcers?